NCT04947501Active, not recruitingEarly phase 1
A Study of N9 Chemotherapy in Children With Neuroblastoma
N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
The purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, carboplatin, and etoposide (ICE), Cyclophosphamide, doxorubicin, and vincristine (CDV).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- First submitted
- 23 Jun 2021
- Start date
- 22 Jun 2021
- Primary completion date
- 22 Jun 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Neuroblastoma, Childhood cancers
- NCT number
- NCT04947501
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 26
- From 22 Jun 2021 to the primary completion date, 22 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity ≥ grade 3.
Other
- Inability to comply with protocol requirements.
- Pregnancy is not an issue because all patients will be pre-adolescents.
Who the study is looking for
- Diagnosis of NB as defined by histopathology (confirmed by the MSK Department of Pathology), BM metastases plus high urine catecholamine levels, or positivity in MIBG scan.
- HR-NB, defined as MYCN-amplified stage 2/3/4/4S at any age and stage 4 in patients \>18 months old.
- No more than one prior cycle of chemotherapy.
- Age \<19 years old.
- Signed informed consent indicating awareness of the investigational nature of this treatment.
Age in the registry: 1 year to 19 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.